目的 探討通宣理肺顆粒聯(lián)合頭孢丙烯治療小兒急性上呼吸道感染的臨床療效。方法 選取2021年1月—2022年10月廣西中醫(yī)藥大學(xué)第一附屬醫(yī)院收治的226例急性上呼吸道感染患兒，按隨機(jī)數(shù)字表法將所有患兒分為對照組和治療組，每組各113例。對照組口服頭孢丙烯顆粒，每次7.5 mg/kg，2次/d。治療組在對照組基礎(chǔ)上口服通宣理肺顆粒，1～3歲1/3袋/次；4～6歲1/2袋/次；7歲以上1袋/次；2次/d。兩組療程均為5 d。觀察兩組臨床療效、主要表現(xiàn)消失時(shí)間，比較治療前后兩組兒童睡眠習(xí)慣問卷（CSHQ）評分、兒少心理健康量表（MHS-CA）評分、兒童生活質(zhì)量量表4.0（Peds QLTM4.0）評分及全血白細(xì)胞計(jì)數(shù)（WBC）、中性粒細(xì)胞比例（NEUT%）、C反應(yīng)蛋白（CRP）、降鈣素原（PCT）水平。結(jié)果 治療后，治療組總有效率為96.46%，顯著高于對照組的88.50%（P＜0.05）。治療組發(fā)熱、咳嗽、咽痛、鼻塞、流涕消失時(shí)間均較對照組顯著更短（P＜0.05）。治療后，兩組CSHQ評分均顯著降低，而MHS-CA、Peds QLTM4.0評分均顯著增高（P＜0.05）；且治療后，CSHQ、MHS-CA、Peds QLTM4.0評分均以治療組改善更顯著（P＜0.05）。治療后，兩組全血WBC、NEUT%、CRP、PCT水平均顯著下降（P＜0.05）；且治療后，治療組WBC、NEUT%、CRP、PCT水平低于對照組（P＜0.05）。結(jié)論 通宣理肺顆粒聯(lián)合頭孢丙烯治療小兒急性上呼吸道感染具有較好的臨床療效，能有效加速患兒主要臨床表現(xiàn)的消失，抑制機(jī)體感染及炎癥狀態(tài)，使睡眠、心理及生活質(zhì)量得到有效改善，值得臨床推廣應(yīng)用。

Objective To explore the clinical efficacy of Tongxuan Lifei Granules combined with cefprozil in treatment of children with acute upper respiratory tract infection. Methods A total of 226 children with acute upper respiratory tract infection admitted to the First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine from January 2021 to October 2022 were selected and divided into control group and treatment group according to random number table method, with 113 cases in each group. Patients in control group were po administered with Cefprozil Granules, 7.5 mg/kg each time, twice daily. Patients in the treatment group were po administered with Tongxuan Lifei Granules on the basis of the control group, 1 — 3 years old 1/3 bag/time; 4 — 6 years old 1/2 bag/time; over 7 years old 1 bag/time; twice daily. The treatment course of both groups was 5 d. The clinical efficacy and disappearance time of main manifestations were observed in the two groups. The Sleep Habits Questionnaire (CSHQ) scores, Children’s Mental Health Scale (MHS-CA) scores, and Children’s Quality of Life Scale 4.0 (Peds QLTM4.0) scores, whole blood white blood cell count (WBC), neutrophil ratio (NEUT%), C-reactive protein (CRP), and procalcitonin (PCT) were compared between two groups before and after treatment. Results After treatment, the total effective rate of treatment group was 96.46%, which was significantly higher than that of control group (88.50%, P＜0.05). The disappearance time offever, cough, sore throat, stuffy nose, and runny nose in treatment group was significantly shorter than that in control group (P＜0.05). After treatment, CSHQ scores were significantly decreased in both groups, but MHS-CA and Peds QLTM4.0 scores were significantly increased (P＜0.05). After treatment, CSHQ, MHS-CA and Peds QLTM4.0 scores were significantly improved in treatment group (P＜0.05). After treatment, whole blood WBC, NEUT%, CRP, and PCT levels were significantly decreased in both groups (P＜ 0.05). After treatment, the levels of WBC, NEUT%, CRP, and PCT in treatment group were lower than those in control group (P＜0.05). Conclusion Tongxuan Lifei Granules combined with cefprozil has good clinical efficacy in treatment of children with acute upper respiratory tract infection, and can effectively accelerate the disappearance of the main clinical manifestations of children, inhibit the infection and inflammation of the body, and effectively improve the sleep, psychology and quality of life, which is worthy of clinical promotion and application.

R974

廣西中醫(yī)藥大學(xué)廣西一流學(xué)科建設(shè)項(xiàng)目（2018xk002）